Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Svea Bank AB in connection with the issuance of callable tier 2 capital bonds (T2) of SEK 300 million
Mandate

Vinge has advised Svea Bank AB in connection with the issuance of callable tier 2 capital bonds (T2) of SEK 300 million

June 14, 2024 Banking and Finance

Vinge has advised Svea Bank AB in connection with its issuance of SEK 300 million callable tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 6.75%. The issue date is set to 7 June 2024, and the bonds have a maturity of 10.25 years with first permitted redemption date after 5 years. The instruments will be listed on Nasdaq Stockholm.

Vinge’s team consisted of Mikael Ståhl, Felix Möller and Sofia Haggren.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026